Erratum to: Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation (Pediatric Blood & Cancer, (2013), 60, 6, (1044-1047), 10.1002/pbc.24437);Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation

Pediatric Blood and Cancer

Volumn 60, Issue 6, 2013, Pages 1044-1047

  Grupp, Stephan A ^a   Dvorak, Christopher C ^b   Nieder, Michael L ^c   Levine, John E ^d   Wall, Donna A ^e   Langholz, Bryan ^f   Pulsipher, Michael A ^g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

SCT; Stem cell transplantation; Transplantation

Indexed keywords

CORTICOSTEROID; ETANERCEPT; METHOTREXATE; RAPAMYCIN; TACROLIMUS;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IDIOPATHIC PNEUMONIA SYNDROME; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; UMBILICAL CORD BLOOD;

EID: 84876437018     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.26353     Document Type: Erratum

References (19)

1. Frangoul H, Nemecek ER, Billheimer D, et al. A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. Blood 2007; 110: 4584-4587.
2. Yanik GA, Ho VT, Levine JE, et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2008; 112: 3073-3081.
3. Uberti JP, Ayash L, Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 680-687.
4. Yanik G, Hellerstedt B, Custer J, et al. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 395-400.
5. Brown VI, Hulitt J, Fish J, et al. Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. Cancer Res 2007; 67: 9963-9970.
6. Brown VI, Seif AE, Reid GS, et al. Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunol Res 2008; 42: 84-105.
7. Cooperman J, Neely R, Teachey DT, et al. Cell division rates of primary human precursor B cells in culture reflect in vivo rates. Stem Cells 2004; 22: 1111-1120.
8. Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009; 145: 569-580.
9. Teachey DT, Obzut DA, Cooperman J, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006; 107: 1149-1155.
10. Teachey DT, Sheen C, Hall J, et al. mTOR inhibitors are synergistic with methotrexate: An effective combination to treat acute lymphoblastic leukemia. Blood 2008; 112: 2020-2023.
11. Pulsipher MA, Wall DA, Grimley M, et al. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol 2009; 147: 691-699.
12. Pulsipher M, Langholz B, Wall D, et al. A randomized trial of sirolimus-based graft versus host disease (GVHD) prophylaxis after hematopoietic stem cell tansplantation (HSCT) in selected patients with CR1 and CR2 ALL: Results from Children's Oncology Group study ASCT 0431. Blood 2011; 118: 731.
13. Kreissman SG, Villablanca JG, Seeger RC, et al. A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged versus unpurged PBSC: A Children's Oncology Group study. J Clin Oncol 2008; 26: 10011.
14. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOG-MDS/EBMT trial. Blood 2005; 105: 410-419.
15. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
16. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci Transl Med 2011; 3: 95ra73.
17. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17: 1453-1464.
18. Barrett DM, Zhao Y, Liu X, et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 2011; 2212: 1575-1586.
19. Grupp SA, June CH. Adoptive cellular therapy. Curr Top Microbiol Immunol 2011; 344: 149-172.